Literature DB >> 32303527

Mesalamine-induced eosinophilic pleural effusion.

Abdullah Al-Abcha1, Fazal Raziq2, Shouq Kherallah2, Ahmad Alratroot2.   

Abstract

A 45-year-old woman with a medical history of ulcerative colitis (UC) presented with difficulty in breathing. The patient was diagnosed with UC a month prior to presentation and was started on mesalamine suppository. Chest x-ray (CXR) on presentation showed bilateral pleural effusion, which was confirmed on CT angiogram of the chest. Diagnostic and therapeutic thoracentesis was performed and 0.7 L of pleural fluid was removed from the left side. The pleural fluid analysis was consistent with exudative pleural effusion with eosinophilia. Symptomatic improvement was noted after thoracentesis. Mesalamine was stopped and repeat CXR was obtained on the follow-up visit, which showed no pleural effusion. The Naranjo score was calculated to be 7, indicating that the eosinophilic pleural effusion was most probably secondary to adverse reaction from mesalamine. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: gastrointestinal system; respiratory medicine; ulcerative colitis; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2020        PMID: 32303527      PMCID: PMC7199113          DOI: 10.1136/bcr-2019-233886

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Mesalamine-associated pleural effusion with pulmonary infiltration.

Authors:  G P Sesin; N Mucciardi; S Almeida
Journal:  Am J Health Syst Pharm       Date:  1998-11-01       Impact factor: 2.637

Review 2.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

3.  Mesalazine-induced Pleuropericarditis in a Patient with Crohn's Disease.

Authors:  Hidemichi Kiyomatsu; Kazushige Kawai; Toshiaki Tanaka; Jyunichiro Tanaka; Tomomichi Kiyomatsu; Hiroaki Nozawa; Takamitsu Kanazawa; Shinsuke Kazama; Soichiro Ishihara; Hironori Yamaguchi; Eiji Sunami; Toshiaki Watanabe
Journal:  Intern Med       Date:  2015-07-01       Impact factor: 1.271

4.  Carbimazole-induced eosinophilic pleural effusion.

Authors:  Chris Ferguson; Claire Bradley; Joe Kidney
Journal:  BMJ Case Rep       Date:  2018-05-07

Review 5.  Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.

Authors:  Irene Sonu; Ming Valerie Lin; Wojciech Blonski; Gary R Lichtenstein
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

Review 6.  Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence.

Authors:  R Trisolini; R Dore; F Biagi; O Luinetti; P Pochetti; N Carrabino; M Luisetti
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2000-10       Impact factor: 0.670

7.  Incidence and aetiology of eosinophilic pleural effusion.

Authors:  R Krenke; J Nasilowski; P Korczynski; K Gorska; T Przybylowski; R Chazan; R W Light
Journal:  Eur Respir J       Date:  2009-04-22       Impact factor: 16.671

Review 8.  Pathogenesis of the eosinophilic pleural effusions.

Authors:  Ioannis Kalomenidis; Richard W Light
Journal:  Curr Opin Pulm Med       Date:  2004-07       Impact factor: 3.155

Review 9.  Eosinophilic pleural effusions.

Authors:  Ioannis Kalomenidis; Richard W Light
Journal:  Curr Opin Pulm Med       Date:  2003-07       Impact factor: 3.155

10.  Acute eosinophilic pneumonia related to a mesalazine suppository.

Authors:  Jung Hyun Kim; June-Hyuk Lee; Eun-Suk Koh; Sung Woo Park; An-Soo Jang; Dojin Kim; Choon-Sik Park
Journal:  Asia Pac Allergy       Date:  2013-04-26
View more
  1 in total

1.  Incidence, aetiology and clinical features of eosinophilic pleural effusion: a retrospective study.

Authors:  Minfang Li; Yunxiang Zeng; Sheng Chen; Jinlin Wang; Yaqing Li; Dan Jia
Journal:  BMC Pulm Med       Date:  2021-12-06       Impact factor: 3.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.